Skip to main content

Rallybio Corp

RLYB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001739410

No open-market purchases or sales by Rallybio Corp insiders were filed in the last 90 days; 37 institutions reported holding it in 13F filings for Q2 2026, worth $65.0M in total; Viking Global Investors is the only superinvestor holding it.

Q2 2022 vs. Q1 2022

How the institutions holding Rallybio Corp changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of RLYB: Q1 2022 compared with Q2 2022
MeasureQ1 2022Of which not filed for Q2 2022Q2 2022Change
Holders47147+1
Shares27.8M1.06K27.7M−115.2K (−0.4%)
Value$193.9M$7.00K$208.8M+$14.9M (+7.7%)

1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Rallybio Corp at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to RLYB in Q2 2022
InstitutionSharesValue% of portfolio
VR Adviser, LLC268,532$2.03M0.40%
Alps Advisors Inc19,060$144.0K0.00%
Acadian Asset Management LLC10,188$77.0K0.00%
Mercer Global Advisors Inc10,000$76.0K0.00%
Credit Suisse AG24$00.00%
Ellevest, Inc.4$00.00%

Sold out (5)

Institutions that held Rallybio Corp at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of RLYB in Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Walleye Capital LLC59,543$416.0K
Renaissance Technologies LLC52,715$368.0K
Jump Financial, LLC20,800$145.0K
Trexquant Investment LP15,798$110.0K
Allspring Global Investments Holdings, LLC4,449$31.0K

Not filed for Q2 2022 yet (1)

Institutions that held Rallybio Corp at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding RLYB in Q1 2022 that haven't filed for Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Amalgamated Financial Corp.1,060$7.00K